MiR-492 as an important biomarker for early diagnosis and targeted treatment in different cancers

Eskandar Taghizadeh, Forough Taheri, Daryoush Rostami, Pedram G. Renani, Gordon A. Ferns, Alireza Pasdar*, Majid G. Mobarhan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Recent studies have led to a more detailed understanding of the roles played by microRNAs in health and disease, and their potential use as biomarkers in physiological and pathophysiological processes involving cancer initiation and progression. MiR-492 is encoded by a pseudogene, has a key role in some human cancer cells and its overexpression in tissues, and it has been proposed that it can be used as a good biomarker for management and early diagnosis of some cancers including breast cancer, colorectal and ovarian cancer, hepatocellular cancer, retinoblastoma and pancreatic cancer. The aim of this review was to summarize the data of MiR-492 for early diagnosis and treatment of some types of related cancers.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalCurrent Cancer Therapy Reviews
Volume16
Issue number4
DOIs
Publication statusPublished - 20 Nov 2020

Keywords

  • Biomarker
  • Breast cancer
  • Colorectal cancer
  • MicroRNAs
  • MiR-492
  • RNA-silencing

Fingerprint Dive into the research topics of 'MiR-492 as an important biomarker for early diagnosis and targeted treatment in different cancers'. Together they form a unique fingerprint.

Cite this